おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Geron
company
About
Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
- 101 - 250
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $125M
- Industries
- Biopharma,Biotechnology,Health Diagnostics,Pharmaceutical
- Founded date
- Aug 28, 1990
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is a product candidate in clinical development.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$125M
Geron has raised a total of
$125M
in funding over 2 rounds. Their latest funding was raised on
Jun 30, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 30, 2022 | Post-IPO Debt | $125M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Geron is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hercules Capital
|
— | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
